Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment : Episode 4
Opinion
Video
Patient Selection for Chemotherapy-Based Combination Regimens in Metastatic Prostate Cancer
Author(s):
Key Takeaways
- Chemotherapy is often selected for aggressive or advanced-stage cancers requiring rapid tumor reduction.
- Patients with specific genetic mutations may benefit more from targeted therapies than chemotherapy.
The panelist discusses how patient characteristics, disease factors, and individual health status guide the decision to include or avoid chemotherapy in combination treatments for metastatic prostate cancer, weighing potential benefits against risks and quality of life considerations.
Video Player is loading.
Video Content above is prompted by the following:
- For which patients would you choose or avoid a combination that includes chemotherapy?
Related Videos
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Checkpoint Inhibitors for Treatment of NMIBC
Communication of Treatment Options for High-Risk NMIBC
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
BPH: The Patient Journey
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
Addressing Remaining Unmet Needs in mCRPC
Use and Sequencing of Novel Treatments in NMIBC
The DORA Trial
Related Content
